Gabapentin/Pregabalin in uraemic pruritis and restless legs syndrome in patients with end-stage renal failure. Renal supportive care is an emerging subspecialty with a focus on symptom management and end of life care in end-stage renal disease patients. Whilst the evidence base is growing, most symptom management is extrapolated from other areas of medicine. Uraemic pruritis and restless legs syndrome have been increasingly recognised as problematic symptoms secondary to end-stage renal disease. Both symptoms are common (up to 30% of end stage renal disease patients) and often severe and have a negative impact on quality of life. There are some randomised controlled trials that are in favour of managing these symptoms with gabapentinoids. The pharmacology and side effect profile of medications is often complex in this patient cohort. Dosing adjustments are required in both conservatively managed (not for dialysis) patients and patients on dialysis. There are no postmarketing or pharmacovigilance studies in this patient cohort. This study will provide information to prescribers of the side effect profile of a gabapentinoids in real life end-stage renal failure patients. Rapid collection of these data will improve the evidence base whilst more time and resource intensive randomised controlled trials are being developed.

To join this Series

- For new sites visit the website or contact the RAPID Research Assistant, Jane Hunt.
- For existing sites download the case report form and start data collection.

Contact

Jane Hunt
RAPID Research Assistant
PaCCSC - Palliative Care Clinical Studies Collaborative
E: RAPID@uts.edu.au
W: https://uts.edu.au/RAPID
@pa_ccsc